HepaLife Technologies to expand drug delivery operations

Recently, HepaLife Technologies released its plans to expand it's transdermal drug delivery technology. According to Fierce Drug Delivery, they plan to pinpoint this unit on their recent acquisition of AquaMed Technologies, which took place this past May. Alliqua's and HepaLife's current signature technology is transdermal delivery with high water content, electron beam cross-linked aqueous polymer sheet hydrogels.

HepaLife President Richard Rosenblum stated, "We are pleased to announce the formation of Alliqua, as we believe it will drive HepaLife's existing and developmental product pipeline going forward. As we proactively penetrate the expanding drug delivery and wound care industries, we remain highly committed to growing our revenue, earnings and, ultimately, shareholder value."